Drug Shortage Report for MILRINONE LACTATE INJECTION, USP

Last updated on 2023-04-03 History
Report ID 173932
Drug Identification Number 02244622
Brand name MILRINONE LACTATE INJECTION, USP
Common or Proper name MILRINONE LACTATE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) MILRINONE
Strength(s) 1MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 10 mL
ATC code C01CE
ATC description CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Reason for shortage Other (Please describe in comments)
Anticipated start date 2022-11-01
Actual start date 2022-11-01
Estimated end date 2023-03-31
Actual end date 2023-03-31
Shortage status Resolved
Updated date 2023-04-03
Company comments Effective February 1, 2023, allocations to cover 100% of historical monthly demand of 10 mL and 100% of historical monthly demand of 20 mL at a 2:1 ratio. Please see communication for further details.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v6 2023-04-03 French Compare
v5 2023-04-03 English Compare
v4 2023-03-01 French Compare
v3 2023-03-01 English Compare
v2 2022-11-07 French Compare
v1 2022-11-07 English Compare

Showing 1 to 6 of 6